Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Lung transplantation: Donor lung preservation

Marcelo Cypel, MD, MSc
Tom Waddell, MD, MSc, PhD, FRCS, FACS
Shaf Keshavjee, MD, MSc, FRCSC, FACS
Section Editor
Elbert P Trulock, MD
Deputy Editor
Helen Hollingsworth, MD


Donor lung preservation refers to the process of maintaining and protecting a donor lung from the time of lung procurement up until implantation in the recipient. Many factors such as temperature, perfusion volume and pressure, oxygenation, and degree of inflation may impact the likelihood of lung injury during storage or at the time of reperfusion, and also the function of the lung after transplantation.

Much of the experimental work in lung transplantation over the past decade has focused on optimizing methods of lung preservation to reduce the impact of ischemia-reperfusion injury on post-transplant lung function.

The preservation of donor lungs for lung transplantation will be reviewed here. An overview of lung transplantation and discussions of donor evaluation and management, the lung transplantation procedure, early postoperative care, and primary graft dysfunction are provided separately. (See "Lung transplantation: An overview" and "Lung transplantation: Deceased donor evaluation and management" and "Lung transplantation: Procedure and postoperative management" and "Primary lung graft dysfunction".)


The donor lung procurement operation is coordinated with cardiac procurement, such that the lungs and the heart may routinely be used for separate recipients (table 1) [1]. Key goals include preventing in situ thrombosis and vasospasm and stabilizing the lung for static cold storage. Lung donation after brain death or cardiac death is discussed separately. (See "Lung transplantation: Deceased donor evaluation and management", section on 'Donation after brain death' and "Lung transplantation: Deceased donor evaluation and management", section on 'Donation after cardiac death'.)

Donation after brain death — The lung procurement operation is usually performed through a median sternotomy [1,2]. In sequence, the pulmonary arteries are dissected free from the ascending aorta and the superior vena cava is dissected free up to the innominate bifurcation. After the heart and lungs are exposed, the donor is anticoagulated with intravenous heparin (300 units per kg). A perfusion cannula is placed in the pulmonary artery at least 1.5 cm distal to the pulmonary valve. A cardioplegia catheter is placed in the ascending aorta. (See "Diagnosis of brain death".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Mar 9, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Puri V, Patterson GA. Adult lung transplantation: technical considerations. Semin Thorac Cardiovasc Surg 2008; 20:152.
  2. Pasque MK. Standardizing thoracic organ procurement for transplantation. J Thorac Cardiovasc Surg 2010; 139:13.
  3. Daemen JW, Kootstra G, Wijnen RM, et al. Nonheart-beating donors: the Maastricht experience. Clin Transpl 1994; :303.
  4. Bernat JL, Capron AM, Bleck TP, et al. The circulatory-respiratory determination of death in organ donation. Crit Care Med 2010; 38:963.
  5. Cypel M, Levvey B, Van Raemdonck D, et al. International Society for Heart and Lung Transplantation Donation After Circulatory Death Registry Report. J Heart Lung Transplant 2015; 34:1278.
  6. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167:490.
  7. de Perrot M, Bonser RS, Dark J, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005; 24:1460.
  8. Hopkinson DN, Bhabra MS, Hooper TL. Pulmonary graft preservation: a worldwide survey of current clinical practice. J Heart Lung Transplant 1998; 17:525.
  9. Fischer S, Matte-Martyn A, De Perrot M, et al. Low-potassium dextran preservation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg 2001; 121:594.
  10. Veith FJ, Sinha SB, Graves JS, et al. Ischemic tolerance of the lung. The effect of ventilation and inflation. J Thorac Cardiovasc Surg 1971; 61:804.
  11. Steen S, Sjöberg T, Massa G, et al. Safe pulmonary preservation for 12 hours with low-potassium-dextran solution. Ann Thorac Surg 1993; 55:434.
  12. Keshavjee SH, Yamazaki F, Cardoso PF, et al. A method for safe twelve-hour pulmonary preservation. J Thorac Cardiovasc Surg 1989; 98:529.
  13. Strüber M, Wilhelmi M, Harringer W, et al. Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation. Eur J Cardiothorac Surg 2001; 19:190.
  14. Müller C, Fürst H, Reichenspurner H, et al. Lung procurement by low-potassium dextran and the effect on preservation injury. Munich Lung Transplant Group. Transplantation 1999; 68:1139.
  15. Aziz TM, Pillay TM, Corris PA, et al. Perfadex for clinical lung procurement: is it an advance? Ann Thorac Surg 2003; 75:990.
  16. Rega, F, Verleden, G, Vanhaecke, J, et al. Switch from Euro-Collins to Perfadex for pulmonary graft preservation resulted in superior outcome in transplant recipients. J Heart Lung Transplant 2003; 22 Suppl 1:S111.
  17. Rabanal JM, Ibañez AM, Mons R, et al. Influence of preservation solution on early lung function (Euro-Collins vs Perfadex). Transplant Proc 2003; 35:1938.
  18. Thabut G, Vinatier I, Brugière O, et al. Influence of preservation solution on early graft failure in clinical lung transplantation. Am J Respir Crit Care Med 2001; 164:1204.
  19. Arnaoutakis GJ, Allen JG, Merlo CA, et al. Low potassium dextran is superior to University of Wisconsin solution in high-risk lung transplant recipients. J Heart Lung Transplant 2010; 29:1380.
  20. Keshavjee SH, Yamazaki F, Yokomise H, et al. The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation. J Thorac Cardiovasc Surg 1992; 103:314.
  21. Oto T, Griffiths AP, Rosenfeldt F, et al. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg 2006; 82:1842.
  22. Marasco SF, Bailey M, McGlade D, et al. Effect of donor preservation solution and survival in lung transplantation. J Heart Lung Transplant 2011; 30:414.
  23. Mühlfeld C, Müller K, Pallesen LP, et al. Impact of preservation solution on the extent of blood-air barrier damage and edema formation in experimental lung transplantation. Anat Rec (Hoboken) 2007; 290:491.
  24. Miñambres E, González-Castro A, Rabanal JM, et al. [Comparative study of two preservation solutions in the initial function after bilateral human lung transplantation]. Med Intensiva 2007; 31:1.
  25. Okada Y, Kondo T. Impact of lung preservation solutions, Euro-Collins vs. low-potassium dextran, on early graft function: a review of five clinical studies. Ann Thorac Cardiovasc Surg 2006; 12:10.
  26. Puskas JD, Cardoso PF, Mayer E, et al. Equivalent eighteen-hour lung preservation with low-potassium dextran or Euro-Collins solution after prostaglandin E1 infusion. J Thorac Cardiovasc Surg 1992; 104:83.
  27. Novick RJ, Menkis AH, McKenzie FN. New trends in lung preservation: a collective review. J Heart Lung Transplant 1992; 11:377.
  28. Christie, NA, Waddell, TK. Lung preservation. Chest Surg Clin N Am 1993; 3:29.
  29. de Perrot M, Fischer S, Liu M, et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines. Transplantation 2001; 72:1505.
  30. Gohrbandt B, Sommer SP, Fischer S, et al. Iloprost to improve surfactant function in porcine pulmonary grafts stored for twenty-four hours in low-potassium dextran solution. J Thorac Cardiovasc Surg 2005; 129:80.
  31. Kirk AJ, Colquhoun IW, Dark JH. Lung preservation: a review of current practice and future directions. Ann Thorac Surg 1993; 56:990.
  32. Novick RJ, Gehman KE, Ali IS, Lee J. Lung preservation: the importance of endothelial and alveolar type II cell integrity. Ann Thorac Surg 1996; 62:302.
  33. Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 2008; 85:278.
  34. Pegg DE. Organ preservation. Surg Clin North Am 1986; 66:617.
  35. Müller C, Hoffmann H, Bittmann I, et al. Hypothermic storage alone in lung preservation for transplantation: a metabolic, light microscopic, and functional analysis after 18 hours of preservation. Transplantation 1997; 63:625.
  36. Venuta F, Rendina EA, Bufi M, et al. Preimplantation retrograde pneumoplegia in clinical lung transplantation. J Thorac Cardiovasc Surg 1999; 118:107.
  37. Strüber M, Hohlfeld JM, Kofidis T, et al. Surfactant function in lung transplantation after 24 hours of ischemia: advantage of retrograde flush perfusion for preservation. J Thorac Cardiovasc Surg 2002; 123:98.
  38. Tanaka H, Chiba Y, Sasaki M, et al. Relationship between flushing pressure and nitric oxide production in preserved lungs. Transplantation 1998; 65:460.
  39. Sasaki M, Muraoka R, Chiba Y, Hiramatu Y. Influence of pulmonary arterial pressure during flushing on lung preservation. Transplantation 1996; 61:22.
  40. DeCampos KN, Keshavjee S, Liu M, Slutsky AS. Optimal inflation volume for hypothermic preservation of rat lungs. J Heart Lung Transplant 1998; 17:599.
  41. Kayano K, Toda K, Naka Y, Pinsky DJ. Identification of optimal conditions for lung graft storage with Euro-Collins solution by use of a rat orthotopic lung transplant model. Circulation 1999; 100:II257.
  42. Eberlein M, Reed RM, Permutt S, et al. Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation. J Heart Lung Transplant 2012; 31:1207.
  43. Wang LS, Yoshikawa K, Miyoshi S, et al. The effect of ischemic time and temperature on lung preservation in a simple ex vivo rabbit model used for functional assessment. J Thorac Cardiovasc Surg 1989; 98:333.
  44. Ganesh JS, Rogers CA, Banner NR, et al. Does the method of lung preservation influence outcome after transplantation? An analysis of 681 consecutive procedures. J Thorac Cardiovasc Surg 2007; 134:1313.
  45. Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18:425.
  46. Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005; 171:786.
  47. Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005; 129:423.
  48. Okabayashi K, Aoe M, DeMeester SR, et al. Pentoxifylline reduces lung allograft reperfusion injury. Ann Thorac Surg 1994; 58:50.
  49. Shaw MJ, Shennib H, Bousette N, et al. Effect of endothelin receptor antagonist on lung allograft apoptosis and NOSII expression. Ann Thorac Surg 2001; 72:386.
  50. Kawashima M, Nakamura T, Schneider S, et al. Iloprost ameliorates post-ischemic lung reperfusion injury and maintains an appropriate pulmonary ET-1 balance. J Heart Lung Transplant 2003; 22:794.
  51. Wittwer T, Franke UF, Fehrenbach A, et al. Donor pretreatment using the aerosolized prostacyclin analogue iloprost optimizes post-ischemic function of non-heart beating donor lungs. J Heart Lung Transplant 2005; 24:371.
  52. Reece TB, Laubach VE, Tribble CG, et al. Adenosine A2A receptor agonist improves cardiac dysfunction from pulmonary ischemia-reperfusion injury. Ann Thorac Surg 2005; 79:1189.
  53. Pizanis N, Milekhin V, Tsagakis K, et al. PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation. Eur J Cardiothorac Surg 2007; 32:42.
  54. Sommer SP, Gohrbandt B, Fischer S, et al. Glutathione improves the function of porcine pulmonary grafts stored for twenty-four hours in low-potassium dextran solution. J Thorac Cardiovasc Surg 2005; 130:864.
  55. Gao W, Zhao J, Kim H, et al. α1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death. J Heart Lung Transplant 2014; 33:309.
  56. Yeung JC, Wagnetz D, Cypel M, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther 2012; 20:1204.
  57. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1:4ra9.
  58. Maathuis MH, Leuvenink HG, Ploeg RJ. Perspectives in organ preservation. Transplantation 2007; 83:1289.
  59. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364:1431.
  60. Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87:255.
  61. Zych B, Popov AF, Stavri G, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant 2012; 31:274.
  62. Wallinder A, Ricksten SE, Hansson C, et al. Transplantation of initially rejected donor lungs after ex vivo lung perfusion. J Thorac Cardiovasc Surg 2012; 144:1222.
  63. Cypel M, Yeung JC, Machuca T, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 2012; 144:1200.
  64. Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27:1319.
  65. Cypel M, Rubacha M, Yeung J, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9:2262.
  66. Tikkanen JM, Cypel M, Machuca TN, et al. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Heart Lung Transplant 2015; 34:547.